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INPP5K (Inositol Polyphosphate 5-Phosphatase K, or SKIP (for Skeletal muscle and 
Kidney enriched Inositol Phosphatase) is a member of the phosphoinositide 5-
phosphatases family. Its protein structure is comprised of a N-terminal catalytic 
domain which hydrolyses both PtdIns(4,5)P2 and PtdIns(3,4,5)P3, followed by a 
SKICH domain at the C-terminus which is responsible for protein-protein interactions 
and subcellular localization of INPP5K. Strikingly, INPP5K is mostly concentrated in 
the endoplasmic reticulum, although it is also detected at the plasma membrane, in 
the cytosol and the nucleus. Recently, mutations in INPP5K have been detected in 
patients with a rare form of autosomal recessive congenital muscular dystrophy with 
cataract, short stature and intellectual disability. INPP5K functions extend from 
control of insulin signaling, endoplasmic reticulum stress response and structural 
integrity, myoblast differentiation, cytoskeleton organization, cell adhesion and 
migration, renal osmoregulation, to cancer. The goal of this review is thus to 
summarize and comment recent and less recent data in the literature on INPP5K, in 
particular on the structure, expression, intracellular localization, interactions and 





Phosphatidylinositol (PtdIns) is composed of a glycerol backbone esterified to two 
fatty acid chains and a phosphate, and attached to a polar head group, the cyclic 
polyol myo-inositol, that extends into the cytoplasm. This inositol head group has free 
hydroxyl groups at positions D2 through D6, and those at positions D3, D4 and D5 
can be phosphorylated into 7 potential combinations by 3-, 4- and 5-kinases, 
respectively. The 7 phosphorylated forms of phosphatidylinositol are named 
phosphoinositides, are present in cell membranes and play important role in many 
biological processes, essentially by interacting with specific proteins (Grabon et al., 
2019). Indeed, each cellular membrane compartment has a characteristic 
composition of phosphoinositide species, and this phosphoinositide signature attracts 
a specific set of functionally important proteins to that membrane, or directly 
regulates the activity level of integral membrane proteins (Falkenburger et al., 2010). 
Beside kinases, phosphoinositide metabolism is also regulated by members of 
phospholipases C and phosphatases families. Phosphates added at positions D3, D4 
and D5 of the inositol head group by kinases can be removed by 3-, 4- and 5-
phosphatases, respectively (Blero et al., 2007). The mammalian 5-phosphatases 
family comprises 10 members. These members share an inositol 5-phosphatase 
domain with a set of conserved amino acids and a general comparable structural 
organization. Except for one member, INPP5A, they all catalyze the 
dephosphorylation of PtdIns(4,5)P2 and/or PtdIns(3,4,5)P3 at the 5- position, 
generating PtdIns(4)P and/or PtdIns(3,4)P2, respectively (Ramos et al., 2019a). 
Interestingly, 5-phosphatase isoenzymes have been individually implicated in human 
diseases, such as ciliopathies (INPP5E), the oculo-cerebrorenal syndrome of Lowe 
(INPP5F) or opsismodysplasia, a rare congenital skeletal dysplasia (INPPL1) (Ramos 
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et al., 2019). The goal of this review is to summarize and comment recent and less 
recent data in the literature on INPP5K, in particular on the in vivo function of this 
member of the 5-phosphatases family in man and genetically-modified animals.        
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Official full name/symbol and synonym: 
The official full name for the INPP5K gene is Inositol Polyphosphate 5-Phosphatase 
K. However, SKIP (for Skeletal muscle and Kidney enriched Inositol Phosphatase) 
was first used when this 5-phosphatase was discovered by Takenawa’s team in 2000 
(Ijuin et al., 2000).  
INPP5K gene, transcripts and proteins in man and mouse: 
The human INPP5K gene is located on the telomeric region of the short arm of 
chromosome 17 (17p13.3), on the reverse strand between nucleotides 1,494,577 
and 1,516,742. The gene comprises 12 exons and generates a 2,706 bp transcript 
coding for a 448 amino acids protein with a theoretical 51.1 kDa molecular mass 
(Figure 1; e!Ensembl). Many splice variants of INPP5K are reported in public 
databases, giving potential proteins of 84 to 229 amino acids in length. However, the 
in vivo relevance of these transcripts is currently unknown. By contrast, two 
interesting transcripts containing insertions of 231 and 390 bp between exon 1 and 2 
of the 2,706 bp transcript described above have been reported (Ijuin et al., 2000; 
e!Ensembl). They both lead to the production of the same 372 amino acids/42.7 kDa 
protein that lacks the first 76 amino acids of the 51.1 kDa INPP5K protein, probably 
by using a second Start codon present in exon 3. Both ~51.1 and ~42.7 kDa signals 
were detected in tissue and cell line protein extracts by Western blotting using an 
affinity-purified rabbit antibody directed against amino acid residues 137-448 of the 
human INPP5K protein (Ijuin et al., 2000). An additional ~36 kDa signal of unknown 
amino-acid sequence was also detected by Western blotting using an affinity-purified 
rabbit antibody raised against a fusion peptide representing the N- and C-terminal 
seven amino acids of human 51.1 kDa INPP5K protein (Gurung et al., 2003). 
7 
 
In mouse, the Inpp5k gene is located on the long arm of chromosome 11 (11qB5), on 
the forward strand between nucleotides 75,630,988 and 75,648,871. The mouse 
Inpp5k gene also comprises 12 exons, as in man, and generates a 2,679 bp 
transcript coding for a 468 amino acids protein with a theoretical molecular mass of 
54.2 kDa (e!Ensembl). Two splice variants giving potential proteins of 39 and 112 
amino acids in length are reported in the databases, but their in vivo relevance is 
unknown. When mouse tissues protein extracts were probed by Western blotting with 
an affinity-purified rabbit antibody raised against the RSFLREDTLYEPEPQI carboxy-
terminal peptide of the INPP5K mouse protein, ~54 and ~42 kDa signals were clearly 
detected (Pernot et al., 2011). A third ~51 kDa signal was specifically observed in 
testis and brain and, in the kidney, a fourth ~36 kDa signal was also present in 
addition to the ~42 kDa signal (Pernot et al., 2011). The exact amino-acid sequence 
and origin of these 51, 42 and 36 kDa signals are currently unknown.  
In conclusion, these results indicate that mouse and human INPP5K genes have a 
very similar structure and lead to the production of full length 54.2 and 51.1 kDa 
catalytically active INPP5K proteins, respectively. Additional truncated INPP5K 
proteins probably also arise from either alternative splicing, the use of alternative 
Start codon or simply from partial proteolysis, which are also detected by Western 
blotting with specific antibodies. The exact biological activity of these truncated 
proteins is currently unknown.  
Expression of INPP5K mRNAs and proteins in human and mouse tissues and 
cells: 
Results from Northern blotting, RT-PCR and Western blotting indicate that 
expression of INPP5K mRNA and protein is rather ubiquitous in human and mouse 
tissues and cells lines (Ijuin et al., 2000; Pernot et al., 2011). Importantly, INPP5K is 
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particularly abundant in skeletal muscle, heart, brain, kidney, testis and eye (see 
below). Hematopoietic cells also express INPP5K mRNA and protein, including 
resting and activated lymphocytes, neutrophils, macrophages and dendritic cells 
(Pernot et al., 2011).  
In addition to the full length 54.2 kDa mouse and 51.1 kDa human INPP5K proteins, 
mouse 51, 42 and 36 kDa signals as well as human 42.7 and 36 kDa signals were 
detected by Western blotting (Ijuin et al., 2000; Gurung et al., 2003; Pernot et al., 
2011). Intriguingly, tissues and cell lines express either a single INPP5K protein or a 
combination of full length and/or truncated INPP5K proteins. For example, the mouse 
C2C12 cell line and mouse ovary only express the 42 kDa truncated protein. By 
contrast, full length 54.2 kDa and truncated 42 kDa proteins are both detected in 
mouse spleen. The most intriguing combination is probably in the mouse kidney 
where a very strong 36 kDa signal is associated with faint 54.2, 51 and 42 signals in 
the cortex, whereas faint 42 and 36 kDa signals are detected in the medulla (Pernot 
et al., 2011). 
Physiological and physiopathological conditions associated with an increased 
INPP5K mRNA/protein expression include skeletal muscle cell differentiation (Xiong 
et al., 2011; Ijuin and Takenawa, 2012a), endoplasmic reticulum stress and activation 
of the unfold protein response (Ijuin et al., 2015a) as well as insulin resistance, 
obesity and diabetes (Ijuin et al., 2015a). In cancer, INPP5K mRNA expression was 
found either significantly increased (endometrial carcinoma (Hedberg Oldfors et al., 
2015), prostate cancer (Flaig et al., 2017), glioblastoma (Davies et al., 2015), renal 
cancer (Jones et al., 2005)) or decreased (lung adenocarcinoma (Gao et al., 2017), 
glioblastoma (Davies et al., 2015)), depending on the cancer cell type. 
Human and mouse INPP5K protein structure and catalytic activity: 
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When compared to the human 448 amino-acids/51.1 kDa INPP5K protein, the mouse 
468 amino-acids/54.2 kDa INPP5K protein is characterized by the presence of an 
additional peptide of 18 residues of unknown function at the N-terminus. With the 
exception of this peptide at the N-terminus, human and mouse INPP5K protein 
structure is identical and simple: a catalytic domain comprising of the two conserved 
and specific motifs of the 5-phosphatases family is present at the amino-terminus of 
the protein (residues 12-326 of the human 51.1 kDa protein and 30-345 of the murine 
54.2 kDa protein), followed by a SKICH domain at the carboxy-terminus (residues 
332-431 of the human 51.1 kDa protein and 351-450 of the murine 54.2 kDa protein) 
(Figure 1). Accordingly, the human 372 amino acids/42.7 kDa protein described 
above, which lacks the first 76 amino acids of the 51.1 kDa full length INPP5K 
protein, is unlikely to harbor 5-phosphatase activity.  
INPP5K hydrolyses both PtdIns(4,5)P2 and PtdIns(3,4,5)P3, but exhibits greatest 
activity towards PtdIns(4,5)P2 (Ijuin et al., 2000; Gurung et al., 2003; Schmid et al., 
2004; Pernot et al., 2011). No phosphatase activity was detected against 
PtdIns(3,5)P2, PtdIns(5)P, Ins(1,4,5)P3 or Ins(1,3,4,5)P4 (Gurung et al., 2003; 
Schmid et al., 2004). 
The ~100 amino-acid SKICH domain (for SKIP carboxy-homology domain) has an Ig-
like β-barrel structure and a molecular surface dominated by negatively charged 
regions which may interact with components of the plasma membrane (Yang et al., 
2015). The SKICH domain and surrounding sequences present at the C-terminus of 
INPP5K mediates interactions with specific proteins and regulate intracellular 
localization (Gurung et al., 2003; Dong et al., 2018). For example, after growth 
factor/insulin stimulation, the SKICH domain mediates INPP5K translocation from its 
endoplasmic reticulum localization in basal conditions to the plasma membrane. The 
10 
 
SKICH domain of INPP5K is composed of a core sequence allowing a constitutive 
plasma membrane association and of surrounding sequences specific to INPP5K that 
contribute to endoplasmic reticulum localization of the protein in basal conditions 
(Gurung et al., 2003, Dong et al., 2018). 
INPP5K interacting proteins: 
Lists of proteins potentially interacting with the INPP5K protein are available in 
BioGRID (37 potential interactors), CORUM (1 potential complex: ID 2639, the HES1 
promoter-Notch enhancer complex), IntAct (38 potential interactors), MINT (7 
potential interactors) and STRING (10 predicted functional partners) public databases 
and are summarized on www.uniprot.org/uniprot/Q9BT40. The present review will be 
limited to 6 interacting proteins which have been carefully analyzed by different 
teams as part of specific studies on INPP5K. 
GRP78/BiP/HSP5a and activated PAK1: 
Ijuin and collaborators proposed a model in which, in basal conditions, cytosolic 
INPP5K directly interacts via its SKICH domain with GRP78/Glucose regulated 
protein 78, a luminal ER chaperone protein involved in ER stress and the UPR (Ijuin 
and Takenawa, 2012b, 2015a, 2015b, 2015c and 2016). However, in this model, the 
unresolved issue is how INPP5K which is present in the cytosol and at the cytosolic 
side of the ER membrane interacts with luminal ER GRP78 (Ijuin et al., 2016). After 
insulin stimulation, the INPP5K-GRP78 complex migrates from ER to the plasma 
membrane, where activated PAK1/p21-activated protein kinase 1 competitively binds 
through a 11 amino-acids peptide within its kinase domain to INPP5K in place of 
GRP78, linking INPP5K to the complex of proteins associated with the insulin 
receptor. Binding of INPP5K to activated PAK1 and this complex via its SKICH 
domain leads to PtdIns(3,4,5)P3 dephosphorylation, decreased AKT2 
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phosphorylation and insulin signaling inactivation (see below for the physiologic 
effect of this regulation). The co-immunoprecipitation of expressed tagged INPP5K 
and GRP78 proteins was reproduced by another team (Wiessner et al., 2017).    
SODD/BAG4: 
According to Rahman and collaborators, the direct interaction between the molecular 
co-chaperone SODD/Silencer of Death Domains and INPP5K following growth factor 
stimulation exerts an inhibitory effect on INPP5K PtdIns(3,4,5)P3 5-phosphatase 
catalytic activity. Consequently, this interaction enhances the recruitment of 
PtdIns(3,4,5)P3-effectors at the plasma membrane and reduces that of 
PtdIns(3,4)P2, resulting in a tight regulation of actin polymerization, cell adhesion, 
spreading and migration (Rahman et al., 2011). Upon growth factor stimulation, 
SODD co-localized with INPP5K both in the cytosol and at the plasma membrane. No 
interaction was detected in basal conditions. In contrast, SODD-/- mouse embryonic 
fibroblasts exhibited reduced AKT phosphorylation following growth factor 
stimulation, associated with increased INPP5K PtdIns(3,4,5)P3-5-phosphatase 
activity (Rahman et al., 2011). 
ARL6IP1:  
ARL6IP1/ADP Ribosylation Factor Like GTPase 6 Interacting Protein 1 is a protein 
with reticulon-like features whose mutations result in hereditary spastic paraplegia, a 
pathology frequently associated with dysfunction of proteins that control ER 
morphology (Blackstone et al., 2011; Novarino et al., 2014; Yamamoto et al, 2014; 
Nizon et al., 2018). ARL6IP1 is embedded in the ER membrane via 4 transmembrane 
domains but its N- and C-terminal regions protrude in the cytosol (Dong et al., 2018). 
Dong and collaborators convincingly demonstrated that the interaction with ER 
ARL6IP1 protein is responsible for INPP5K recruitment from the cytosol to the 
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cytosolic side of the ER membrane and that, like ARL6IP1, INPP5K is enriched in 
newly formed ER tubules. Importantly, knockdown of either protein resulted in 
structural ER alterations (Dong and al., 2018; Ramos et al., 2020). The ARL6IP1 
cytosolic N-terminal region and a surface of INPP5K at the interface of the catalytic 
domain and the SKICH domain were implicated in the INPP5K-ARL6IP1 interaction 
(Dong et al., 2018). 
MAD2L1BP/p31(comet)/CMT2: 
Yeast-two-hybrid analysis revealed MAD2L1BP/MAD2L1 binding protein, a nuclear-
enriched protein binding to the mitotic spindle assembly checkpoint MAD2A protein 
during cell cycle surveillance, as a potential INPP5K interactor (Rual et al., 2005). In 
EGFP-INPP5K-expressing HeLa cells, mCherry-MAD2L1BP co-expression resulted 
in a massive translocation of INPP5K from ER to the nucleus and in a marked 
nuclear INPP5K accretion (Dong et al., 2018). However, the interaction between 
native proteins was not analyzed and interacting domains in INPP5K and MAD2L1BP 
proteins were not defined. Thus, the physiological relevance of this interaction 
remains to be defined. 
2/5C HBV core protein: 
Interestingly, the SKICH domain of INPP5K was reported to interact with amino acids 
116-149 of the 2/5C human hepatitis B virus (HBV) core protein (Hung et al., 2009). 
The interaction with 2/5C HBV core protein induces INPP5K migration from ER to the 
nucleus.   
Intracellular localization of INPP5K: 
In non-stimulated conditions, immunofluorescence studies revealed that both 
endogenous and exogenous tagged INPP5K proteins are mostly concentrated in the 
ER, co-localizing with calreticulin and calnexin ER markers, and that little or no 
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staining is detected at the plasma membrane (Ijuin et al., 2000; Gurung et al., 2003, 
Dong et al., 2018, Ramos et al., 2018, 2020). As mentioned above, at the cytosolic 
side of the ER membrane, INPP5K binds to the N-terminal region of ARL6IP1 which 
protrudes in the cytosol (Dong et al., 2018). Interaction of INPP5K with luminal ER 
GRP78 has also been described, but the molecular mechanism is still unresolved 
(Ijuin et al., 2016). It is noteworthy here that mammalian INPP5K shares this ER 
localization with the yeast phosphoinositide 5-phosphatase Inp54p. Inp54p is a 44 
kDa protein which consists of a N-terminal PtdIns(4,5)P2 5-phosphatase domain and 
a C-terminal leucine-rich tail that is sufficient to target the protein to the cytosolic side 
of the ER membrane (Wiradjaja et al., 2001). After growth factor or insulin 
stimulation, INPP5K is transiently translocated from the ER to the plasma membrane, 
where it could bind to activated PAK1, SODD or still undefined plasma membrane 
ligands via its SKICH domain (see above). At the plasma membrane, INPP5K co-
localizes with submembranous actin at the leading edge of the cell, specifically at 
membrane ruffles (Gurung et al., 2003; Ijuin and Takenawa, 2003, 2012b, 2016). 
Finally, Ramos and collaborators recently reported that INPP5K, beside its known 
ER, plasma membrane and cytosolic localizations, is also present in the nucleus of 
the human U-251 malignant glioblastoma (MG) cell line (Ramos et al., 2020). In this 
cell line, about half of the nuclear INPP5K staining co-localized with SC-35+ speckles, 
where PtdIns(4,5)P2 has been previously detected.   
INPP5K mutations are responsible for a rare form of autosomal recessive 
congenital muscular dystrophy with cataract, short stature and intellectual 
disability in man: 
In 2017, 2 research teams reported that biallelic mutations in the INPP5K gene cause 
a form of congenital muscular dystrophy with early-onset cataract, short stature and 
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cognitive impairment (gene/locus MIM: 607875; phenotype MIM: 617404) (Wiessner 
et al., 2017; Osborn et al., 2017). A total of 9 causative INPP5K alleles were 
identified: 7 in the catalytic region and 2 in the SKICH domain (Figure 1). All 7 
catalytic mutants and one of the SKICH domain mutant (p.Asn417Lysfs*26) exhibited 
moderate to severe decrease in PtdIns(4,5)P2 phosphatase activity in vitro, as 
compared with control INPP5K protein (Wiessner et al., 2017; Osborn et al., 2017). 
The second SKICH domain mutant, p.Ile363Thr, had normal PtdIns(4,5)P2 
phosphatase activity but displayed a striking tendency for a more diffuse intracellular 
distribution in transfected cells than control INPP5K protein (Wiessner et al., 2017). It 
is noteworthy here that patients homozygous for the p.Ile50Thr catalytic mutant had a 
variable penetrance for muscular dystrophy and intellectual disability, leaving in one 
patient the ocular manifestation as the main phenotype and suggesting a role for 
epigenetic factors and/or genetic modifiers in the phenotype (Yousaf et al., 2018). 
Electromyography showed myopathic changes in the muscles of all affected 
individuals tested, in association with normal sensory and motor nerve conduction. 
Muscle pathology was largely non-specific, showing variable degrees of dystrophic 
features, including increased range of muscle fiber size and diameter, muscle 
fibrosis, excess adipose tissue, occasional fibers with centrally located nuclei or 
vacuoles, rare necrotic fibers, and a few basophilic regenerating fibers. There were 
no abnormalities of blood vessels, inflammatory changes, or group atrophy. 
Immunohistochemical analysis of classical skeletal muscle markers was normal, 
except for α-dystroglycan expression, which was reduced in 2 of the 12 affected 
individuals tested (Wiessner et al., 2017; Osborn et al., 2017). Transmission electron 
microscopy revealed several fibers with pronounced reduction of myofibrils and 
disrupted Z line material (Wiessner et al., 2017). Unfortunately, attempts to identify 
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alterations in biological processes in which INPP5K had been previously implicated 
(see below) were unsuccessful, and thus the pathogenic mechanism of this rare 
congenital muscle disease remains totally unknown. Indeed, skin fibroblasts from 
individuals homozygous for the p.Ile50Thr INPP5K mutation and from control 
subjects showed no difference in AKT phosphorylation in response to IGF-II 
stimulation, in the expression of markers of the unfolded protein response (UPR, an 
ER stress reaction), nor in the levels of autophagy markers in response to rapamycin 
and bafilomycin A1 treatment. Finally, all 4 INPP5K mutant proteins tested, including 
p.Ile363Thr in the SKICH domain, bound to GRP78 in a similar way to control 
INPP5K (Wiessner et al., 2017). In connection with the congenital muscular 
dystrophy observed in human INPP5K mutants, it is important to note that 3 single 
nucleotide polymorphisms (SNPs) located in intron 1 and 6 as well as in exon 12 of 
the porcine INPP5K gene have been associated with some meat traits, including 
muscle fiber number (Xiong et al., 2011, 2012). Furthermore, INPP5K gene-modified 
PpsBrdm1/+ heterozygous mice had higher amounts of quadriceps muscle compared 
with wild-type mice (Ijuin et al., 2008).        
INPP5K functions in cellular and animal models: 
The zebrafish as a model for the human congenital muscular dystrophy caused by 
biallelic mutations in the INPP5K gene: 
Inpp5k is present in two copies in the zebrafish genome: inpp5ka and inpp5kb, with 
48 and 44% identity to human INPP5K, respectively. At 1 and 2 days post-fertilization 
(dpf), mRNA quantification indicated that inpp5ka is respectively 7- and 16-fold higher 
expressed than inpp5kb (Osborn et al., 2017). In vivo experiments were conducted 
either by injecting inpp5ka-, inpp5kb- or inpp5ka- and Inpp5kb-specific morpholinos 
(MOs) in embryos (Osborn et al., 2017; Wiessner et al., 2017), or on a zebrafish line 
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carrying an inpp5ka nonsense allele (p.Gln440*, resulting in a C-terminal 12 amino 
acids deletion, a probable hypomorph allele) (Yousaf et al., 2018). Injections of 
inpp5ka or inpp5ka and inpp5kb MOs in fertilized oocytes led to a phenotype that 
closely resembles the human presentation, including myopathy, reduced mobility, 
lens disorganization, microphtalmia, reduced growth, and microcephaly. In contrast, 
inpp5kb MOs alone showed only a very mild phenotype. Histologically, sparser and 
disorganized myofibers, altered sarcomere assembly, and reduced synaptic 
formation were observed in skeletal muscle of inpp5k knockdown embryos. In inpp5k 
morphans, the lens cortex was disorganized and cell nuclei were present in the 
center of the lens nucleus, a phenotype reminiscent of congenital cataracts in man. 
The p.Gln440* zebrafish line displayed a very similar lens phenotype, while the 
skeletal muscle phenotype was much less severe than observed in MOs-injected 
embryos (Yousaf et al., 2018).    
Insulin signaling and insulin resistance: 
As already mentioned above, according to Ijuin and collaborators, INPP5K is 
localized at the cytosolic side of the ER membrane in non-stimulated conditions, 
directly interacting with ER luminal GRP78 (Ijuin and Takenawa, 2012b, 2015a, 
2015b, 2015c and 2016). Following insulin stimulation, the INPP5K-GRP78 complex 
migrates to the plasma membrane, where activated PAK1 competitively binds to 
INPP5K in place of GRP78, linking INPP5K to the complex of proteins associated 
with the insulin receptor. Binding of INPP5K to this complex through activated PAK1 
leads to PtdIns(3,4,5)P3 dephosphorylation, decreased AKT2, p70 S6 kinase and 
Glycogen Synthase activation, GLUT4 translocation, membrane ruffle formation and 
results in insulin signaling inactivation. Inversely, decreasing INPP5K expression in 
cells or in INPP5K gene-modified PpsBrdm1/+ heterozygous mice resulted in an 
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increased insulin signaling and sensitivity in muscle cells and, in PpsBrdm1/+ mice, a 
reduced diet-induced obesity (Ijuin and Takenawa, 2003, 2008; Xiong et al., 2009). 
Finally, INPP5K expression was increased in skeletal muscles isolated from high fat 
diet-fed mice and diabetic/obese db/db mice, as compared to wild-type mice, linking 
INPP5K to these diseases (Ijuin et al., 2015a). In this context, it is noteworthy that 
culture medium supplementation with a synthetic peptide containing the amino acids 
sequence of the PAK1 kinase domain which interacts with INPP5K increased insulin 
signaling in muscle cell lines, probably by interfering with the formation of the 
INPP5K-PAK1 complex (Ijuin and Takenawa, 2015b). 
ER stress, the unfolded protein response (UPR) and insulin resistance: 
The UPR is triggered essentially in response to ER defects in N-linked glycosylation 
and disulfide bond formation, leading to accumulation of unfolded/misfolded proteins 
in the ER lumen (i.e. ER stress). ER stress can be secondary to intracellular 
alterations (e.g., calcium or redox imbalances, glucose deprivation), 
microenvironmental conditions (e.g., hypoglycemia, hypoxia, acidosis, viral infection), 
high-fat diet/obesity, a variety of natural compounds (e.g., thapsigargin, tunicamycin), 
and several prescription drugs. Physiological processes like a vigorous protein 
production and secretion (e.g. immunoglobulins in plasma cells, digestive enzymes in 
exocrine pancreas and intestine) or muscle cell contraction during intense/prolonged 
exercise also trigger the UPR. The GRP78 molecular chaperone, one of the INPP5K 
interacting proteins (see above), plays a central role in the UPR by binding to and 
inactivating 3 stress sensors present in the ER membrane: IRE1α, ATF6 and PERK. 
Briefly, accumulation of unfolded/misfolded proteins in the ER lumen displaces the 
GRP78 chaperone from these sensors to exposed hydrophobic residues on 
abnormally folded proteins. Activation of these 3 sensors results in fine in a 
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decreased protein translation, increased production of molecular chaperones 
involved in protein folding, degradation of unfolded proteins by the proteasome and 
cell cycle arrest. If the UPR is prolonged or failed, cellular apoptosis occurs. Ijuin and 
colleagues showed that UPR activation lead to an increased expression of INPP5K 
mRNA and protein in C2C12 muscle cells and this contributed, as explained above, 
to decreased insulin signaling, i.e. insulin resistance. (Ijuin et al., 2016). XBP1 
transcription factor was involved in this increased expression. Increased skeletal 
muscle INPP5K expression was also observed in diet-induced and genetic models of 
obesity in mice where the UPR is chronically activated, suggesting a link between 
high-fat diet, obesity, the UPR (including XBP1), INPP5K expression and insulin 
resistance.     
ER structural integrity: 
Dong and collaborators elegantly demonstrated that INPP5K interacts with the N-
terminus of ARL6IP1 at the cytosolic side of the ER membrane (Dong et al., 2018). 
Both proteins are enriched in highly motile, elongating peripheral ER tubules, relative 
to perinuclear ER sheets, and were absent from the nuclear membrane. Interestingly, 
knock-down of INPP5K or ARL6IP1 resulted in a similar decrease in ER tubules and 
expansion of ER sheets at the cell periphery. Both the INPP5K SKICH domain and 5-
phosphatase activity were shown to be essential to keep a normal ER structure. Yet, 
using GFP-PH PLCδ1 as a fluorescent probe to monitor PtdIns(4,5)P2 levels, no 
change in the localization and/or level of the fluorescent signal was detected in 
INPP5K knock-down cells (Dong et al., 2018). Defects in ER architecture and lower 
abundance of peripheral ER tubules were also observed in C. elegans neurons and 
human glioblastoma cell lines when INPP5K (or CIL-1, its C. elegans orthologue) was 
silenced (Dong et al., 2018; Ramos et al., 2020). Importantly, three CIL-1 mutations 
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(I39T, Y261C, and I327T) corresponding to INPP5K mutations found in human 
muscular dystrophic patients did not rescue the ER morphology phenotype when 
expressed in C. elegans CIL-1-deficient neurons, on the contrary to the wild type CIL-
1 protein (Dong et al., 2018).     
Myoblasts differentiation and control of the IGF-II autocrine regulatory loop: 
Expression of INPP5K mRNA and protein increased during C2C12 cell differentiation 
into myotubes. In addition, MyoD, a transcription factor essential for myoblast 
specification during embryogenesis and in adults, induced INPP5K mRNA expression 
in these cells, partly via cis-acting elements in the INPP5K promoter (Xiong et al., 
2011; Ijuin and Takenawa, 2012a). C2C12 cell differentiation into myotubes was 
decreased when INPP5K was overexpressed and, inversely, endogenous INPP5K 
silencing was associated with increased myotubes formation. A model was proposed 
by Ijuin and colleagues where INPP5K controls the IGF-II autocrine regulatory loop 
and thus myoblast differentiation (Ijuin and Takenawa, 2012a). Indeed, during 
myoblast differentiation, IGF-II up-regulates its own gene expression through the 
PI3kinase/PtdIns(3,4,5)P3/AKT/mTOR signaling pathway, leading to IGF-II 
production and secretion in the extracellular space. Secreted IGF-II binds to IGF-1 
receptor on myoblasts and initiate an autocrine/paracrine loop that plays a major role 
during differentiation (Ren et al., 2008; Duan et al., 2010; Jiao et al., 2013, and 
references therein). In the proposed model, INPP5K dephosphorylates 
PtdIns(3,4,5)P3 in the IGF-II signaling pathway, leading to decreased AKT/mTOR 
phosphorylation and IGF-II mRNA and protein production, acting thus as a brake on 
this positive autocrine loop. This mechanism could explain why INPP5K 
overexpression in C2C12 cells decreased myoblast differentiation and why 
decreased endogenous INPP5K expression in these cells and in INPP5K gene-
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modified PpsBrdm1/+ heterozygous mice led to significantly increased differentiation 
into myotubes and quadriceps muscle weight compared to controls (Ijuin et al., 2008, 
2012a).     
Cytoskeleton organization, cell adhesion and migration: 
Following cell stimulation by growth factors like Epidermal Growth factor (EGF) or 
integrin activation during cell adhesion, INPP5K translocates from the ER to the 
plasma membrane and co-localized with submembranous actin and membrane 
ruffles (Gurung et al., 2003; Ijuin and Takenawa, 2003; Davies et al., 2015; Ramos et 
al., 2019b). In these conditions, decreasing INPP5K expression in cancer cell lines 
had no impact on cell proliferation or survival, but resulted in increased PtdIns(4,5)P2 
levels and decreased cell migration (Davies et al., 2015; Ramos et al., 2019b). By 
contrast, INPP5K overexpression suppressed growth factor-induced 
PtdIns(3,4,5)P3/AKT signaling and cell growth, and reduced the recruitment of 
PI(4,5)P2-binding proteins to the plasma membrane, lamellipodia formation and Talin 
incorporation into focal adhesions (Davies et al., 2015).  
Renal osmoregulation: 
Transgenic mice ubiquitously overexpressing tagged mouse INPP5K protein 
presented defects in water metabolism characterized by a reduced plasma osmolality 
at baseline, a delayed urinary water excretion following a water load, and an 
increased acute response to vasopressin. These defects were associated with the 
expression of the Inpp5k transgene in renal collecting ducts and with alterations in 
the arginine vasopressin/aquaporin-2 signalling pathway in this tubular segment. 
Analysis in a mouse collecting duct mCCD cell line revealed that INPP5K 
overexpression lead to increased expression of the arginine vasopressin receptor 
type 2 and increased cAMP response to arginine vasopressin, providing a basis for 
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increased aquaporin-2 expression and plasma membrane localization with increased 
osmotically-induced water transport. Altogether, these results indicated that INPP5K 
is important for the control of the arginine vasopressin/aquaporin-2 signalling 
pathway and water transport in kidney collecting ducts.    
INPP5K association with other biological processes and human diseases: 
As mentioned above, INPP5K mRNA expression was found either increased or 
decreased in cancer, depending on the cancer cell type, but the exact consequence 
on cancer physiopathology remains unclear. By contrast, Ramos and colleagues 
recently showed that INPP5K depletion in the U-87 MG glioblastoma cell line resulted 
in increased viability and decreased apoptosis, and that these cells generated 
significantly larger tumors when injected in SCID mice, compared with controls 
(Ramos et al., 2020).   
Association studies also revealed links between the INPP5K gene and autophagy 
(Zirin et al., 2015), Parkinson (Nazeri et al., 2015; Zhu et al., 2018; Liu et al., 2019) 
and Alzheimer diseases (Rahman et al., 2020).  
Conclusion, questions and future directions: 
In 2017, mutations in INPP5K have been detected in patients with a rare form of 
autosomal recessive congenital muscular dystrophy. All causative INPP5K alleles 
detected so far result in decreased catalytic activity or altered subcellular localization 
of the protein. Muscle pathology is largely non-specific in patients as in inpp5k 
knockdown zebrafish, a model used to mimic the human disease. Unfortunately, the 
pathogenic mechanism of this muscle disease remains totally unknown. In particular, 
no difference in AKT phosphorylation was detected between patients and control 
fibroblasts in response to IGF-II stimulation, even though numerous cellular studies 
seemed to point this growth factor (or insulin)/PI3kinase/ PtdIns(3,4,5)P3/AKT axis as 
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a good candidate for the pathogenic mechanism of this disease. The precise 
intracellular localization of INPP5K in muscle cells will probably give some ideas 
about the mechanism of action of INPP5K in this cell type and the physiopathology of 
this muscular dystrophy. Precisions about the human phenotype are also needed: 
why do patients with the same INPP5K mutation have so variable penetrance of 
muscular dystrophy and intellectual disability? Are INPP5K patients also insulin 
hypersensitive, like INPP5K gene-modified PpsBrdm1/+ heterozygous mice? 
Conversely, do these INPP5K heterozygous mice have muscle histological 
alterations similar to INPP5K patients or INPP5K-depleted zebrafish?     
More generally, in light of the information in this review, it will be important to discover 
the specific physiological and functional relevance, if any, of human 42.7 and 36 kDa 
as well as mouse 51, 42 and 36 kDa INPP5K proteins, to further analyze the 
interaction of INPP5K with MAD2L1BP and the transfer of this complex into the 
nucleus, as well as the physiological and functional role of INPP5K in this specific 
subcellular compartment, in relation with nuclear PtdIns(4,5)P2 levels. In the same 
line of thought, the impact of INPP5K inactivation on ER functional integrity, beside 
structural integrity (e.g. protein and lipid syntheses, protein glycosylation, calcium 
signaling,…) and on ER phosphoinositide levels should also be investigated. Finally, 
Ijuin and colleagues reported that INPP5K gene-modified PpsBrdm1/Brdm1 homozygous 
mice died early during embryonic life of unknown causes (Ijuin et al., 2008). We have 
generated Inpp5k floxed and then Inpp5kΔ/Δ mice and we could confirm that the latter 
mice died during embryonic life, as PpsBrdm1/Brdm1 mice. Our floxed mice as well as 
those recently generated by McCabe (McCabe et al., 2019) will certainly help to 
answer to most of the above questions and will probably allow discovering the exact 
INPP5K function during eye development and in lens cortex, neurons and brain as 
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well as skeletal muscle. The analysis of INPP5K floxed mice will probably reveal a 
wider phenotype than in INPP5K patients, with alterations involving more biological 
processes and organs, given that human INPP5K mutations do not completely 
abolish the 5-phosphatase catalytic activity or function.   
Altogether, the analysis of this original phosphoinositide 5-phosphatase will certainly 
give some surprising and interesting results about its role and its PtdIns(4,5)P2 and 
PtdIns(3,4,5)P3 substrates in physiology and physiopathology in many organs, cells 
and subcellular localizations.      
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Figure 1: The human INPP5K gene and protein, as well as mutations 
discovered in patients. 
The top panel represents the relationship between exons (blue boxes) and the 5-
phosphatase and SKICH domains of the INPP5K protein. White boxes are 5’ and 3’ 
untranslated regions. The central panel represents the different domains of the 
Rasa3 protein with their known functions. The lower panel shows the 9 mutations 
discovered so far in patients with a rare form of autosomal recessive congenital 
muscular dystrophy.  
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